• Lophius Biosciences

  Participated · Equity · May 2014

  Lophius Biosciences develops and markets T cell-based diagnostic systems to improve therapy control and personalize treatment for transplantation, infectious and autoimmune diseases. Its product portfolio includes the CE-marked in vitro diagnostic solution T-Track® CMV to personalize antiviral CMV therapy in transplant patients and diagnostic efforts based on its Reverse T Cell Technology (RTT) platform. The RTT platform enables differentiation of active T cells versus T memory cells; Lophius recently completed a proof of concept study for differential diagnosis of tuberculosis that distinguishes active contagious disease from latent infection. The company will use the extended funding to accelerate diagnostic developments in the tuberculosis area, further leverage its T cell and immunodiagnostic technology platforms, and strengthen commercialization activities for T-Track® CMV. Lophius completed an additional financing that brought its latest round to €7.4m after a further €2.2m injection. The company is led by CEO Bernd Merkl and is based in Regensburg, Germany. Lophius Biosciences develops and markets T cell–based research tools, contract research solutions and diagnostics for functional assessment of pathogen- and disease-reactive T cells. Its product portfolio includes the T Cell Tool, contract research services and a diagnostic development program based on its proprietary Reverse T Cell Technology. The Reverse T Cell Technology enables differentiation of in‑vivo activated T cells versus T memory cells and, in tuberculosis, allows identification of patients with contagious active disease versus latent infection. Lophius completed a €4.25M financing round led by VRD GmbH with participation from the Bavarian Growth Fund (Wachstumsfonds Bayern) of Bayern Kapital, Wolf Biotech GmbH and WIC GmbH. The company will use the proceeds to expand its in‑vitro diagnostic programs to tuberculosis and to further strengthen market penetration activities for its T Cell Tool and contract research portfolio. Lophius is led by co‑CEOs and Managing Directors Bernd Merkl and Robert Phelps and is based in Regensburg, Germany. Lophius Biosciences, based in Regensburg, Germany, develops and markets innovative T cell-based diagnostic systems. Its flagship product is T-Track® CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in CMV seropositive transplant patients undergoing immunosuppressive therapy. The company also has pipeline products T-Track® TB (Tuberculosis) and T-Track® MS (Multiple Sclerosis). Lophius raised €2M in financing to further advance the clinical studies of T-Track® CMV and to enable further development of its pipeline products. Leadership changes accompanied the financing, with Dr. Robert Phelps named CEO and Prof. Dr. Ralf Wagner appointed Chairman of the Board to help create the commercial organization. Lophius Biosciences is a Regensburg, Germany-based developer and marketer of novel T-cell-based diagnostic test systems led by CEO Dr. Michael Lutz. The company focuses on diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases. It is bringing its T-Track© CMV/EBV tests to market for use in transplantation. Lophius plans further development of a diagnostic test for the differential diagnosis of tuberculosis. The company is also developing a novel, blood-based multiple sclerosis test. Financially, Lophius closed a €1.4m financing round subscribed by existing investors S-Refit, High‑Tech Gründerfonds and Bayernkapital. Lophius Biosciences develops and markets T-cell-based diagnostic test systems for diagnosis and potential therapy guidance in transplantation, infectious and autoimmune diseases. The company is a spin-off of the Universitätsklinik Regensburg and is based in Regensburg, Germany. It uses proprietary technology platforms to generate diagnostic tests and plans to commercialize existing products while developing new assays. To support these activities, Lophius closed a €1.6m second financing round. The funds are intended to boost development with a strong focus on commercialization of existing diagnostic products and the generation of new tests. In conjunction with the financing the company appointed Dr. Michael Lutz as CEO, with PD Dr. Deml and Marc Akteries remaining in leading roles.

No current team members are available.